$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

$supn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000135657622000025 Filed on April 13, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$159.1M	$579.8M	$143.6M
YoY Change	10.76%	11.41%	42.96%
Cost Of Revenue	$16.99M	$75.06M	$18.50M
YoY Change	-8.14%	43.09%	351.22%
Gross Profit	$142.1M	$504.7M	$125.0M
YoY Change	13.64%	7.86%	29.8%
Gross Profit Margin	89.32%	87.05%	87.05%
Selling, General & Admin	$79.44M	$304.8M	$56.20M
YoY Change	41.34%	51.87%	57.42%
% of Gross Profit	55.92%	60.38%	44.96%
Research & Development	$21.08M	$90.47M	$17.90M
YoY Change	17.75%	19.1%	-9.6%
% of Gross Profit	14.84%	17.92%	14.32%
Depreciation & Amortization	$12.71M	$32.60M	$5.500M
YoY Change	131.04%	79.68%	223.53%
% of Gross Profit	8.95%	6.46%	4.4%
Operating Expenses	$113.7M	$395.2M	$82.00M
YoY Change	38.61%	42.87%	47.75%
Operating Profit	$28.40M	$86.03M	$43.00M
YoY Change	-33.96%	-50.47%	5.35%
Interest Expense	-$3.216M	$19.70M	$700.0K
YoY Change	-559.43%	1.34%	-121.21%
% of Operating Profit	-11.32%	22.89%	1.63%
Other Income/Expense, Net	-$831.0K	-$12.85M	-$4.000M
YoY Change	-79.23%	154.53%	-217.65%
Pretax Income	$2.051M	$73.18M	$39.70M
YoY Change	-94.83%	-56.61%	-2.93%
Income Tax	-$391.0K	$19.75M	$8.900M
% Of Pretax Income	-19.06%	26.99%	22.42%
Net Earnings	$2.442M	$53.42M	$30.80M
YoY Change	-92.07%	-57.92%	-7.03%
Net Earnings / Revenue	1.54%	9.21%	21.45%
Basic Earnings Per Share		$1.01
Diluted Earnings Per Share	$44.79K	$0.98	$572.5K
COMMON SHARES
Basic Shares Outstanding	53.18M shares	53.10M shares	52.69M shares
Diluted Shares Outstanding		54.36M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$339.7M	$339.7M	$422.5M
YoY Change	-19.6%	-19.6%	21.72%
Cash & Equivalents	$203.4M	$203.4M	$288.6M
Short-Term Investments	$136.2M	$136.2M	$133.9M
Other Short-Term Assets	$27.02M	$27.02M	$18.70M
YoY Change	44.49%	44.49%	61.21%
Inventory	$85.96M	$85.96M	$48.33M
Prepaid Expenses
Receivables	$148.9M	$148.9M	$140.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$601.6M	$601.6M	$630.4M
YoY Change	-4.57%	-4.57%	33.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.96M	$52.32M	$37.82M
YoY Change	-55.17%	-9.95%	121.61%
Goodwill	$117.5M		$77.91M
YoY Change	50.83%
Intangibles	$784.7M		$364.3M
YoY Change	115.37%		1366.76%
Long-Term Investments	$119.2M	$119.2M	$350.4M
YoY Change	-65.99%	-65.99%	-40.79%
Other Assets	$49.23M	$13.87M	$43.25M
YoY Change	13.83%	-39.71%	97.54%
Total Long-Term Assets	$1.088B	$1.088B	$873.7M
YoY Change	24.48%	24.48%	27.06%
TOTAL ASSETS
Total Short-Term Assets	$601.6M	$601.6M	$630.4M
Total Long-Term Assets	$1.088B	$1.088B	$873.7M
Total Assets	$1.689B	$1.689B	$1.504B
YoY Change	12.3%	12.3%	29.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.331M	$9.331M	$6.147M
YoY Change	51.8%	52.97%	-39.38%
Accrued Expenses	$117.7M	$241.1M	$78.93M
YoY Change	49.09%	27.28%	58.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$315.4M	$315.4M	$245.1M
YoY Change	28.67%	28.67%	52.63%
LONG-TERM LIABILITIES
Long-Term Debt	$379.3M	$379.3M	$361.8M
YoY Change	4.82%	-0.72%	4.81%
Other Long-Term Liabilities	$16.38M	$93.32M	$42.79M
YoY Change	-61.72%	-3.7%	49.32%
Total Long-Term Liabilities	$395.6M	$472.6M	$42.79M
YoY Change	824.57%	-1.32%	49.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$315.4M	$315.4M	$245.1M
Total Long-Term Liabilities	$395.6M	$472.6M	$42.79M
Total Liabilities	$873.3M	$873.3M	$759.2M
YoY Change	15.02%	15.03%	34.41%
SHAREHOLDERS EQUITY
Retained Earnings	$379.9M		$326.5M
YoY Change	16.36%		63.62%
Common Stock	$53.00K		$53.00K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$815.9M	$815.9M	$744.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.689B	$1.689B	$1.504B
YoY Change	12.3%	12.3%	29.63%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$2.442M	$53.42M	$30.80M
YoY Change	-92.07%	-57.92%	-7.03%
Depreciation, Depletion And Amortization	$12.71M	$32.60M	$5.500M
YoY Change	131.04%	79.68%	223.53%
Cash From Operating Activities	$48.76M	$127.1M	$31.90M
YoY Change	52.86%	-8.14%	-27.17%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$2.045M	-$200.0K
YoY Change	-80.0%	-159.29%	-90.0%
Acquisitions		$950.0K
YoY Change		-99.68%
Other Investing Activities	$76.17M	-$79.87M	$49.50M
YoY Change	53.88%	155.17%	130.23%
Cash From Investing Activities	$76.13M	-$81.91M	$49.30M
YoY Change	54.42%	136.07%	152.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$7.095M
YoY Change		62.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-136.7M	-$130.4M	3.100M
YoY Change	-4510.97%	-3764.51%	158.33%
NET CHANGE
Cash From Operating Activities	48.76M	$127.1M	31.90M
Cash From Investing Activities	76.13M	-$81.91M	49.30M
Cash From Financing Activities	-136.7M	-$130.4M	3.100M
Net Change In Cash	-11.85M	-$85.21M	84.30M
YoY Change	-114.05%	-179.44%	30.7%
FREE CASH FLOW
Cash From Operating Activities	$48.76M	$127.1M	$31.90M
Capital Expenditures	-$40.00K	-$2.045M	-$200.0K
Free Cash Flow	$48.80M	$129.2M	$32.10M
YoY Change	52.03%	-4.28%	-29.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001356576
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35518
CY2021	dei	Entity Registrant Name EntityRegistrantName	SUPERNUS PHARMACEUTICALS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2590184
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	9715 Key West Avenue
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2021	dei	City Area Code CityAreaCode	(301)
CY2021	dei	Local Phone Number LocalPhoneNumber	838-2500
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53386305	shares
CY2021	dei	Trading Symbol TradingSymbol	SUPN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1634702733	USD
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203434000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288640000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	136246000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	133893000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	148932000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140877000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	85959000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	48325000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27019000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18682000	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	119166000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	350359000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	16955000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	601590000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	630417000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	37824000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	784693000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	364342000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	117516000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	77911000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	49232000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43249000	USD
CY2021Q4	us-gaap	Assets Assets	1689152000	USD
CY2020Q4	us-gaap	Assets Assets	1504102000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	117683000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	78934000	USD
CY2021Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	132724000	USD
CY2020Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	126192000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	44840000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	30900000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20132000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9082000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	315379000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	245108000	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	379252000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	361751000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	35637000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	45800000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41298000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28579000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	85355000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	35215000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16380000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42791000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	873301000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	759244000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53256094	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53256094	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52868482	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52868482	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	434337000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	409332000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1539000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8975000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	379922000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	326498000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	815851000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	744858000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1689152000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1504102000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	579775000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392755000	USD
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	75061000	USD
CY2020	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	52459000	USD
CY2019	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	16660000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	90467000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75961000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69099000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	304759000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	200677000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	153246000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29989000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15702000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5179000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6530000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1900000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	493746000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	346699000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	244184000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	86029000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	173698000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18141000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6659000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	148571000	USD
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23423000	USD
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23754000	USD
CY2019	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	22707000	USD
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10569000	USD
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18704000	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21623000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12854000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5050000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1084000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	73175000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	168648000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	147487000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53099330	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54356744	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7436000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7436000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1558000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	10575000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45988000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128508000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	123631000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	453023000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14846000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3928000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16561000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4361000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	744858000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17910000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7095000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7436000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	815851000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32595000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	15000000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17501000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16581000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15708000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	17910000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	16561000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	14846000	USD
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	347000	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	4352000	USD
CY2019	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	301000	USD
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-418000	USD
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2889000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	4034000	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	6530000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1900000	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1420000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1454000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2226000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4994000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	568000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5832000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3867000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34607000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15751000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14580000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10124000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	969000	USD
CY2021	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	8398000	USD
CY2020	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	10442000	USD
CY2019	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	2864000	USD
CY2021	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	4502000	USD
CY2020	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	10386000	USD
CY2019	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	566000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18179000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8272000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11683000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	127127000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138399000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	143129000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	530509000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	378422000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	253170000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	311573000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	95890000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	409707000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	950000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	298541000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	310742000	USD
CY2020	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	USD
CY2021	supn	Payments For Proceeds From Collaborative Arrangement Investment PaymentsForProceedsFromCollaborativeArrangementInvestment	-12888000	USD
CY2020	supn	Payments For Proceeds From Collaborative Arrangement Investment PaymentsForProceedsFromCollaborativeArrangementInvestment	15000000	USD
CY2019	supn	Payments For Proceeds From Collaborative Arrangement Investment PaymentsForProceedsFromCollaborativeArrangementInvestment	0	USD
CY2021	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	2045000	USD
CY2020	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	3690000	USD
CY2019	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	1387000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81913000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34699000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157924000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7095000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4361000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3928000	USD
CY2021	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	800000	USD
CY2020	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	0	USD
CY2019	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	0	USD
CY2021	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	138315000	USD
CY2020	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0	USD
CY2019	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0	USD
CY2021	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	USD
CY2020	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	802000	USD
CY2019	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-130420000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3559000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3928000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85206000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107259000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10867000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288640000	USD
CY2019	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	0	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192248000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203434000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288640000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11908000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6949000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	5337000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	25190000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	45428000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51540000	USD
CY2020	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	2478000	USD
CY2021	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	10307000	USD
CY2020	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	76700000	USD
CY2021	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	10868000	USD
CY2019	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	35594000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	22747000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2021	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	25000	USD
CY2020	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	USD
CY2019	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	10151000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has eight commercial products: Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®. In addition, the Company has two late-stage development products included in its product candidates portfolio, including SPN-830 (apomorphine infusion device), an acquired product candidate from the USWM Acquisition. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, the Company's New Drug Application (NDA) for SPN-830 (apomorphine infusion device) was accepted for review by the U.S. Food and Drug Administration (FDA) and was assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 7, 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2021 Adamas Acquisition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement”) by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser). On November 24, 2021, the Purchaser was merged with and into Adamas (the "Merger"), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (the Adamas Acquisition). At the time of the Adamas Acquisition, Adamas had two established commercial products in its portfolio, GOCOVRI and Osmolex ER, in addition to royalty rights to Namzaric. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for further discussion on the Adamas Acquisition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Navitor Development Agreement</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor). Under the terms of the Development Agreement, the Company and Navitor will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) in treatment-resistant depression (TRD). Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the Navitor Development Agreement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2020 USWM Acquisition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2020, the Company entered into a Sale and Purchase Agreement with US WorldMeds Partners, LLC to acquire the CNS portfolio of USWM Enterprises, LLC (USWM Enterprises) (the USWM Acquisition). With the acquisition, completed on June 9, 2020, the Company added three established commercial products, APOKYN, XADAGO, and MYOBLOC, and a product candidate in late-stage development, SPN-830 (apomorphine infusion device), to its portfolio. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion on the USWM Acquisition. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ransomware Incident</span></div><div style="margin-top:10pt;padding-right:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 24, 2021, we announced that we were the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on the preliminary results of the ongoing investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from our systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to our systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. At this time, the Company has successfully recovered the impacted files and has taken additional steps designed to further protect its networks and files. We have not paid any ransom amounts. We have incurred costs in 2021 and expect </span></div><div style="margin-top:10pt;padding-right:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to continue to incur costs in the future, which may be significant, in connection with efforts designed to enhance our data security and take further steps designed to protect against unauthorized access to, or manipulation of, our systems and data. These costs were primarily comprised of certain employee related expenses and various third party consulting services, including forensic experts, legal counsel and other IT and accounting professional expenses, and enhancements to our cyber security measures. We expect to incur additional costs related to the ransomware attack in the future, including costs related to our response to the ransomware incident and our efforts designed to enhance our security measures.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the situation. Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
CY2021	supn	Number Of Proprietary Development Products NumberOfProprietaryDevelopmentProducts	2	product
CY2021	supn	Number Of Proprietary Commercial Products NumberOfProprietaryCommercialProducts	3	product
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts in the consolidated balance sheets, statements of cashflows, and statements of earnings have been reclassified to conform to the current year presentation, including a reclassification made to present amortization of intangible assets separately. This was previously included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and now is recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span> on the consolidated statements of earnings
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on historical experience; various forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believes are reasonable under the circumstances. Actual results could differ materially from the Company's estimates. The Company periodically evaluates the methodologies employed in making its estimates on an ongoing basis. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions (i.e., provision for estimated rebates, provision for estimated future product returns, and an estimated provision for discounts), the creditworthiness of customers entering into revenue arrangements, the valuation of the assets and liabilities acquired in the acquisitions, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div>
CY2021	supn	Sales Return Period SalesReturnPeriod	P12M
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents, marketable securities, and accounts receivable. The counterparties are various corporations, governmental institutions, and financial institutions of high credit standing.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's cash, cash equivalents, and marketable securities are maintained in U.S. government agency debt and debt of well-known, investment grade corporations. Deposits held with banks may exceed the amount of governmental insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and therefore, these bear minimal default risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span>
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021	supn	Sales Return Period Prior To Expiration SalesReturnPeriodPriorToExpiration	P6M
CY2021	supn	Sales Return Period SalesReturnPeriod	P12M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021	us-gaap	Advertising Expense AdvertisingExpense	86000000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	54500000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	40800000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	230000000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	230000000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	579775000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392755000	USD
CY2021	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	9400000	USD
CY2020	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	8500000	USD
CY2019	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	6900000	USD
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	USD
CY2021	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	-1700000	USD
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	USD
CY2019	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	400000	USD
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	253301000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	472306000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2349000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11987000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	238000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	41000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255412000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	484252000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	136246000	USD
CY2021Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One To Year Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneToYearTwo	110869000	USD
CY2021Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Two To Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwoToYearThree	8297000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30000000	USD
CY2021Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three To Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThreeToYearFour	0	USD
CY2021Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFour	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255412000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	12900000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6500000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6500000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	76700000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	10307000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-6530000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-6530000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	80477000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	80477000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	76700000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	80477000	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	117516000	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	117516000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	77911000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	77911000	USD
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P8Y7M17D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	848920000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	64227000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	784693000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	398579000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34237000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15700000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	364342000	USD
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5200000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	82600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	82600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	79800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	79800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	75000000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2021Q4	supn	Number Of Votes Per Common Share Held NumberOfVotesPerCommonShareHeld	1	vote
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2000000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17910000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16561000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14846000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	0	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	146400	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	625100	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	53424000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	126950000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	113056000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53099330	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1257414	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1074474	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1404573	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54356744	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	16606000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29893000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29333000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8196000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11234000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10930000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1651000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2200000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4551000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3400000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1629000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1281000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	15367000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	35417000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	30972000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3088000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7281000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7543000	USD
CY2021	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	1465000	USD
CY2020	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	2654000	USD
CY2019	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	1332000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1016000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3602000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2071000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-314000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	348000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-2992000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	250000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	911000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-400000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-353000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2021Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	6910000	USD
CY2020Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	12420000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	19506000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	17529000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	17802000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13547000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4448000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3151000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	126333000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13164000	USD
CY2021Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	12146000	USD
CY2020Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14542000	USD
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	7860000	USD
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1055000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	7819000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	2501000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	7730000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1613000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4256000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3911000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	214810000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83433000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70529000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	144281000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82851000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	199240000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	79545000	USD
CY2021Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	5671000	USD
CY2020Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	10190000	USD
CY2021Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10689000	USD
CY2020Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10897000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9099000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10674000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4937000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6760000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	229636000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	118066000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	85355000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	35215000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9000	USD
CY2021	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	69697000	USD
CY2020	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	573000	USD
CY2019	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	0	USD
CY2021	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	250000	USD
CY2020	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	0	USD
CY2019	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	2000	USD
CY2021	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	0	USD
CY2020	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	-2000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70500000	USD
CY2019	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70529000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000	USD
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	1600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5881000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8848000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	898000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1027000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	208000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	221000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	363000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	49000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	316000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1345000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3029000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5881000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	USD
CY2021	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	100000	USD
CY2020	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	600000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	3000000	USD
CY2021	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	USD
CY2020	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	200000	USD
CY2021	supn	Unrecognized Tax Benefits Increase Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsIncreaseResultingFromLapseOfApplicableStatuteOfLimitations	200000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2021Q4	supn	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	segment
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35365000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20231000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	20874000	USD
CY2021Q4	supn	Lease Right Of Use Asset LeaseRightOfUseAsset	35365000	USD
CY2020Q4	supn	Lease Right Of Use Asset LeaseRightOfUseAsset	41105000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6477000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3760000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3761000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41298000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28579000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20235000	USD
CY2021Q4	supn	Lease Liability LeaseLiability	47775000	USD
CY2020Q4	supn	Lease Liability LeaseLiability	56335000	USD
CY2021	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	8929000	USD
CY2020	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	5333000	USD
CY2021	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	3059000	USD
CY2020	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	2145000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11988000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7478000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1873000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	333000	USD
CY2021	supn	Financing Lease Cost FinancingLeaseCost	0	USD
CY2020	supn	Financing Lease Cost FinancingLeaseCost	2206000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11908000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6949000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	802000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10868000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2478000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	22747000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0371
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7843000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7733000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6971000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5333000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4626000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	24755000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	57261000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9486000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	47775000	USD
CY2021Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	13500000	USD
CY2020Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	11400000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	54864000	USD
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	7325000	USD
CY2020Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	22208000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	45711000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8985000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	32923000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17132000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	85959000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	48325000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2021	supn	Defined Contribution Plan Employer Match Level One DefinedContributionPlanEmployerMatchLevelOne	1
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	22747000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	33409000	USD
CY2021	supn	Defined Contribution Plan Employer Match Employee Contribution Level One DefinedContributionPlanEmployerMatchEmployeeContributionLevelOne	0.03
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	16454000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	17040000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	16955000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	37824000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2600000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1500000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1900000	USD
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28068000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16008000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13821000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13890000	USD
CY2021Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	9125000	USD
CY2020Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	12842000	USD
CY2021Q4	us-gaap	Inventory Adjustments InventoryAdjustments	18460000	USD
CY2020Q4	us-gaap	Inventory Adjustments InventoryAdjustments	9587000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	26728000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7730000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9331000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6147000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6477000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3760000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5673000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8970000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	117683000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78934000	USD
CY2021Q4	supn	Accrued Rebates AccruedRebates	97597000	USD
CY2020Q4	supn	Accrued Rebates AccruedRebates	96589000	USD
CY2021Q4	supn	Accrued Product Returns AccruedProductReturns	35127000	USD
CY2020Q4	supn	Accrued Product Returns AccruedProductReturns	29603000	USD
CY2021Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	132724000	USD
CY2020Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	126192000	USD
CY2021Q4	supn	Non Recourse Liability Noncurrent NonRecourseLiabilityNoncurrent	5977000	USD
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2020Q4	supn	Non Recourse Liability Noncurrent NonRecourseLiabilityNoncurrent	13410000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20235000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	10403000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	9146000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16380000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42791000	USD
CY2021	us-gaap	Interest Expense InterestExpense	19696000	USD
CY2020	us-gaap	Interest Expense InterestExpense	19435000	USD
CY2019	us-gaap	Interest Expense InterestExpense	18207000	USD
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	3727000	USD
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	4319000	USD
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	4500000	USD
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23423000	USD
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23754000	USD
CY2019	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	22707000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17500000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16600000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15700000	USD
CY2021	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	8800000	USD
CY2020	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	16000000	USD
CY2019	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	21300000	USD
CY2015Q3	supn	Non Recourse Debt Sale Of Future Royalties Noncurrent NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent	30000000	USD
CY2021	supn	Defined Contribution Plan Eligibility Minimum Age DefinedContributionPlanEligibilityMinimumAge	P18Y
CY2021	supn	Defined Contribution Plan Employer Match Level Two DefinedContributionPlanEmployerMatchLevelTwo	0.50
CY2021	supn	Employer Match Employee Contribution Level Two EmployerMatchEmployeeContributionLevelTwo	0.02
CY2021	supn	Defined Contribution Plan Maximum Discretionary Employer Contribution Percentage DefinedContributionPlanMaximumDiscretionaryEmployerContributionPercentage	0.60
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3000000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2600000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	USD

Files In Submission

Name	View Source	Status
0001356576-22-000025-index-headers.html	Edgar Link	pending
0001356576-22-000025-index.html	Edgar Link	pending
0001356576-22-000025.txt	Edgar Link	pending
0001356576-22-000025-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
supn-20211231.htm	Edgar Link	pending
supn-20211231.xsd	Edgar Link	pending
supn-20211231xex21.htm	Edgar Link	pending
supn-20211231xex231.htm	Edgar Link	pending
supn-20211231xex311.htm	Edgar Link	pending
supn-20211231xex312.htm	Edgar Link	pending
supn-20211231xex321.htm	Edgar Link	pending
supn-20211231xex322.htm	Edgar Link	pending
supn-20211231_cal.xml	Edgar Link	unprocessable
supn-20211231_def.xml	Edgar Link	unprocessable
supn-20211231_g1.jpg	Edgar Link	pending
supn-20211231_htm.xml	Edgar Link	completed
supn-20211231_lab.xml	Edgar Link	unprocessable
supn-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2021 Q4 Form 10-K Financial Statement

#000135657622000025 Filed on April 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2021 Q4 Form 10-K Financial Statement

#000135657622000025 Filed on April 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn